Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Tao T, Skiadopoulos MH, Durbin AP, Davoodi F, Collins PL, Murphy BR. Tao T, et al. Among authors: durbin ap. Vaccine. 1999 Mar 5;17(9-10):1100-8. doi: 10.1016/s0264-410x(98)00327-2. Vaccine. 1999. PMID: 10195620
This was used to recover a fully-viable, recombinant chimeric PIV3-PIV1 virus, termed rPIV3-1, which bears the major protective antigens of PIV1 and is wild type-like with regard to growth in cell culture and in hamsters [Tao T, Durbin AP, Whitehead SS, Davoodi F, C …
This was used to recover a fully-viable, recombinant chimeric PIV3-PIV1 virus, termed rPIV3-1, which bears the major protective antigens of …
A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Tao T, Davoodi F, Cho CJ, Skiadopoulos MH, Durbin AP, Collins PL, Murphy BR. Tao T, et al. Among authors: durbin ap. Vaccine. 2000 Jan 31;18(14):1359-66. doi: 10.1016/s0264-410x(99)00406-5. Vaccine. 2000. PMID: 10618533
Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orcutt A, Muratova O, Awkal M, Zhou H, Wang J, Stowers A, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP. Malkin EM, et al. Among authors: durbin ap. Infect Immun. 2005 Jun;73(6):3677-85. doi: 10.1128/IAI.73.6.3677-3685.2005. Infect Immun. 2005. PMID: 15908397 Free PMC article. Clinical Trial.
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. Wu Y, et al. Among authors: durbin ap. PLoS One. 2008 Jul 9;3(7):e2636. doi: 10.1371/journal.pone.0002636. PLoS One. 2008. PMID: 18612426 Free PMC article. Clinical Trial.
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.
Crompton PD, Mircetic M, Weiss G, Baughman A, Huang CY, Topham DJ, Treanor JJ, Sanz I, Lee FE, Durbin AP, Miura K, Narum DL, Ellis RD, Malkin E, Mullen GE, Miller LH, Martin LB, Pierce SK. Crompton PD, et al. Among authors: durbin ap. J Immunol. 2009 Mar 1;182(5):3318-26. doi: 10.4049/jimmunol.0803596. J Immunol. 2009. PMID: 19234231 Free PMC article.
175 results